LitCovid-sentences  

PMC:7324763 / 38336-43410 JSONTXT 14 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T213 0-75 Sentence denotes Table 1 List of COVID-19 clinical trials using immunomodulatory therapies.
T214 76-209 Sentence denotes Category Therapeutic(s) Trial identifier Phase Location (centers) Patients (n) Study eligibility Mechanism of action(s)
T215 210-232 Sentence denotes NK cell-based products
T216 233-346 Sentence denotes       Adoptive NK cells NK cells NCT04280224 I Henan, China 30 Pneumatic COVID19+ Adoptive NK cell therapy
T217 347-465 Sentence denotes CYNK-001 NCT04365101 I/II New Jersey, USA 86 Mild COVID19+ From human placental CD34+ cells and culture-expanded
T218 466-619 Sentence denotes NK cells isolated from healthy donor PBMCs NCT04344548 I/II Bagota, Colombia 10 NEWS of >4 Isolated NK cells ex vivo stimulated with IL-2 and IL-15
T219 620-948 Sentence denotes       CAR-NK Cells NKG2D-ACE2 CAR-NK cell therapy from umbilical cord blood NCT04324996 I/II Chongqing, China 90 Within <14 dpi IL-15 prolongs NK cell lifespan; GM-CSF neutralizing scFV reduces recruitment of inflammatory cells; NKG2D-ACE2 CAR-NK cells can target virally infected cells; ACE2 CAR-NK can act as decoy cell
T220 949-973 Sentence denotes NK cell immunostimulants
T221 974-999 Sentence denotes Direct NK cell activation
T222 1000-1233 Sentence denotes       IFN-α Therapy Recombinant human IFN-α ± Thymosin alpha 1 NCT04320238 III Hubei, China 2,944 Uninfected HCW IFN-alpha boosts immune system; thymosin alpha 1 activates TLRs in myeloid and pDCs leading to NK cell activation
T223 1234-1349 Sentence denotes Recombinant human IFN-α2β NCT04293887 I Hubei, China 328 Within <7 dpi IFN-alpha activates interferon pathway
T224 1350-1459 Sentence denotes Abidol Hydrochloride ± IFN atomization (Peg-IFN-α-2b) NCT04254874 IV Hubei, China 100 Pneumatic COVID19+
T225 1460-1559 Sentence denotes Rintatolimod ± Recombinant IFN-α2β NCT04379518 I/II New York, USA 80 Mild to moderate COVID19+
T226 1560-1704 Sentence denotes       IFN-β Therapy Lopinavir/ritonavir ± IFN-β-1a NCT04315948 III France (3) 3,100 Moderate/Severe IFN-beta activates interferon pathway
T227 1705-1837 Sentence denotes Base therapy ± IFN-β-1a NCT04350671 IV Tehran, Iran 40 Within <10 dpi Base therapy = Hydropinchloroquine + Lopinavir/Ritonavir
T228 1838-1956 Sentence denotes Base therapy ± IFN-β-1b NCT04276688 II Hong Kong, HK 127 NEWS of ≥1 Base therapy = Lopinavir/ritonavir/Ribavirin
T229 1957-2104 Sentence denotes IFN-β-1a vs. IFN-β-1b (+Base therapy) NCT04343768 IV Tehran, Iran 60 Moderate/Severe Base therapy = Hydropinchloroquine + Lopinavir/Ritonavir
T230 2105-2132 Sentence denotes Indirect NK cell activation
T231 2133-2324 Sentence denotes       IFN-λ Therapy Peg-IFN-Lambda-1a NCT04331899 II California, USA 120 Early COVID19+ IFN-lambda to boost NK cells indirectly through Monocytes, Macrophages, and pDCs IL-12 secretion
T232 2325-2392 Sentence denotes Peg-IFN-Lambda-1a NCT04343976 II Boston, USA 40 Early COVID19+
T233 2393-2478 Sentence denotes Peg-IFN-Lambda-1a NCT04354259 II Toronto, Canada 140 Ambulatory and hospitalized
T234 2479-2550 Sentence denotes Peg-IFN-Lambda-1a NCT04388709 II New York, USA 66 Non-ICU COVID19+
T235 2551-2628 Sentence denotes Peg-IFN-Lambda-1a NCT04344600 II Maryland, USA 164 Asymptomatic COVID19+
T236 2629-2655 Sentence denotes Immunoregulatory therapies
T237 2656-2883 Sentence denotes Immune checkpoint blockade Anti-PD-1 (vs. Thymosin) NCT04268537 II Nanjing, China 120 Respiratory failure within <48h of ICU Prevent T-cell regulation by blocking PD-1; in COVID19+ advanced or metastatic cancer patients;
T238 2884-3006 Sentence denotes Anti-PD-1 (pembrolizumab) + tocilizumab NCT04335305 II Nanjing, China 24 Pneumatic COVID19+ Tocilizumab = anti-IL-6R
T239 3007-3118 Sentence denotes Anti-PD-1 (nivolumab) vs. GNS651 NCT04333914 II France (4) 273 Early COVID19+ GNS651 = Chloroquine analog
T240 3119-3157 Sentence denotes Non-specific innate immune stimulation
T241 3158-3334 Sentence denotes       Heterologous vaccines BCG NCT04328441 III Netherlands (9) 1,500 Uninfected HCW Trains and primes innate immunity against subsequent non-specific pathogen infection
T242 3335-3410 Sentence denotes BCG (Danish strain) NCT04327206 III Australia (8) 4,170 Uninfected HCW
T243 3411-3476 Sentence denotes BCG (Danish strain) NCT04350931 III Egypt 900 Uninfected HCW
T244 3477-3538 Sentence denotes BCG (Danish strain) NCT04379336 III South Africa 500 HCW
T245 3539-3603 Sentence denotes BCG (Tice strain) NCT04348370 IV USA (5) 700 Uninfected HCW
T246 3604-3666 Sentence denotes BCG NCT04369794 IV São Paulo, Brazil 1,000 Early COVID19+
T247 3667-3819 Sentence denotes       TLR agonists PUL-042 (CpG ODN) NCT04313023 II Not listed 200 Unifected/asymptomatic Activates TLR2/6/9 leading to innate immune stimulation
T248 3820-3886 Sentence denotes PUL-042 (CpG ODN) NCT04312997 II Texas, USA 100 Within <7 dpi
T249 3887-3936 Sentence denotes Natural health products and alternative medicines
T250 3937-4098 Sentence denotes       Vitamins Vitamin C NCT04323514 N/A Palermo, Italy 500 Pneumatic COVID19+ General immune boosting properties of vitamin C and natural health products
T251 4099-4158 Sentence denotes Vitamin C NCT04264533 II Hubei, China 140 ICU COVID19+
T252 4159-4221 Sentence denotes Vitamin C NCT03680274 III Quebec, Canada 800 ICU COVID19+
T253 4222-4282 Sentence denotes Vitamin C NCT04344184 II Virginia, USA 200 ICU COVID19+
T254 4283-4354 Sentence denotes Vitamin C + Zinc NCT04342728 N/A Ohio, USA 520 Outpatient COVID19+
T255 4355-4470 Sentence denotes Hydroxychloroquine; Azithromycin; Vitamin C, D; and Zinc NCT04334512 II California, USA 600 Low risk COVID-19+
T256 4471-4568 Sentence denotes Hydroxychloroquine; vitamin C, D; and Zinc NCT04335084 II California, USA 600 Uninfected HCW
T257 4569-4703 Sentence denotes Vitamin D NCT04334005 N/A Spain (2) 200 Non-severe COVID19+ Vitamin D is immunomodulatory and prevents nutritional deficiencies.
T258 4704-4874 Sentence denotes Zinc + Vitamin D (cholecalciferol) NCT04351490 N/A Lille, France 3,140 Asymptomatic COVID19+ To treat zinc and vitamin D deficiency and reduce inflammation and ARDS
T259 4875-4951 Sentence denotes High dose Vitamin D (4X) NCT04344041 III France (9) 260 Severe COVID19+
T260 4952-5074 Sentence denotes NEWS, National Early Warning Score; HCW, Healthcare Workers; Peg, pegylated; dpi, days post-infection; As of June 1, 2020.